Rifaximin 200 mg
Rifaximin 200mg — same gut-selective RNA polymerase beta-subunit inhibitory mechanism as RIFATUF 400 and 550, with less than 0.4% systemic absorption. At 200mg per tablet, this is the original traveller's diarrhoea dose (200mg three times daily for 3 days) and provides a flexible lower-dose option for SIBO and IBS-D where sequential dosing titration is preferred. See RIFATUF 400 for full mechanism detail.
Traveller's diarrhoea: 200mg three times daily for 3 days — the original FDA-approved rifaximin indication and the lowest effective dose. SIBO: 200mg three to four times daily for 10–14 days. IBS-D: 200mg three times daily for 14 days. H. pylori salvage regimens where rifaximin is included as a component. The 200mg tablet allows dose flexibility not achievable by splitting 400mg tablets.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
RIFATUF 200 completes the RIFATUF rifaximin portfolio alongside 400mg and 550mg — providing prescribers dose flexibility across the full clinical rifaximin indication spectrum. For gastroenterologists who prefer lower starting doses for SIBO or who follow traveller's diarrhoea protocols specifying 200mg TDS, RIFATUF 200 provides the appropriate tablet strength within a trusted brand.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.